Timing of human chorionic gonadotropin (hCG) hormone administration in IVF/ICSI protocols using GnRH agonist or antagonists: a systematic review and meta-analysis

References

• Al-Inany HG, Youssef MA, Aboulghar M, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2011;11:CD001750
   Google Scholar
• Belaisch-Allart J, Mayenga JM, Grzegorczyk-Martin V, et al. Is it possible to avoid working on weekends in an Assisted Reproductive Technology program? Gynecol Obstet Fertil 2012;40:472–5
   PubMedGoogle Scholar
• Kolibianakis EM, Venetis CA, Bontis J, Tarlatzis BC. Significantly lower pregnancy rates in the presence of progesterone elevation in patients treated with GnRH antagonists and gonadotrophins: a systematic review and meta-analysis. Curr Pharm Biotechnol 2012;13:464–70
   PubMed Web of Science ®Google Scholar
• Venetis CA, Kolibianakis EM, Papanikolaou E, et al. Is progesterone elevation on the day of human chorionic gonadotrophin administration associated with the probability of pregnancy in in vitro fertilization? A systematic review and meta-analysis. Hum Reprod Update 2007;13:343–55
   PubMed Web of Science ®Google Scholar
• Griesinger G, Mannaerts B, Andersen CY, et al. Progesterone elevation does not compromise pregnancy rates in high responders: a pooled analysis of in vitro fertilization patients treated with recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in six trials. Fertil Steril 2013. [Epub ahead of print] pii: S0015-0282(13)03011-2; doi:10.1016/j.fertnstert.2013.08.045
   Google Scholar
• Kyrou D, Al-Azemi M, Papanikolaou EG, et al. The relationship of premature progesterone rise with serum estradiol levels and number of follicles in GnRH antagonist/recombinant FSH-stimulated cycles. Eur J Obstet Gynecol Reprod Biol 2012;162:165–8
   PubMed Web of Science ®Google Scholar
• European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 2001;16:644–51
   PubMed Web of Science ®Google Scholar
• Huang CC, Lien YR, Chen HF, et al. The duration of pre-ovulatory serum progesterone elevation before hCG administration affects the outcome of IVF/ICSI cycles. Hum Reprod 2012;27:2036–45
   PubMed Web of Science ®Google Scholar
• Awwad JT, Farra C, Mitri F, et al. Split daily recombinant human LH dose in hypogonadotrophic hypogonadism: a nonrandomized controlled pilot study. Reprod Biomed Online 2013;26:88–92
   PubMedGoogle Scholar
• Chang HJ, Lee JR, Jee BC, et al. Cessation of gonadotropin-releasing hormone antagonist on triggering day: an alternative method for flexible multiple-dose protocol. J Korean Med Sci 2009;24:262–8
   PubMedGoogle Scholar
• Dimitry ES, Oskarsson T, Conaghan J, et al. Beneficial effects of a 24 h delay in human chorionic gonadotrophin administration during in-vitro fertilization treatment cycles. Hum Reprod 1991;6:944–6
   PubMed Web of Science ®Google Scholar
• Mochtar MH, Custers IM, Koks CA, et al. Timing oocyte collection in GnRH agonists down-regulated IVF and ICSI cycles: a randomized clinical trial. Hum Reprod 2011;26:1091–6
   PubMedGoogle Scholar
• Morley L, Tang T, Yasmin E, et al. Timing of human chorionic gonadotrophin (hCG) hormone administration in IVF protocols using GnRH antagonists: a randomized controlled trial. Hum Fertil (Camb) 2012;15:134–9
   PubMed Web of Science ®Google Scholar
• Kyrou D, Kolibianakis EM, Fatemi HM, et al. Is earlier administration of human chorionic gonadotropin (hCG) associated with the probability of pregnancy in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone (GnRH) antagonists? A prospective randomized trial. Fertil Steril 2011;96:1112–15
   PubMed Web of Science ®Google Scholar
• Tan SL, Balen A, el Hussein E, et al. A prospective randomized study of the optimum timing of human chorionic gonadotropin administration after pituitary desensitization in in vitro fertilization. Fertil Steril 1992;57:1259–64
   PubMed Web of Science ®Google Scholar
• Kolibianakis EM, Albano C, Camus M, et al. Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertil Steril 2004;82:102–7
   PubMed Web of Science ®Google Scholar
• Clark L, Stanger J, Brinsmead M. Prolonged follicle stimulation decreases pregnancy rates after in vitro fertilization. Fertil Steril 1991;55:1192–4
   PubMedGoogle Scholar
• Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from: www.cochrane-handbook.org
   Google Scholar
• Punnonen R, Ashorn R, Vilja P, et al. Spontaneous luteinizing hormone surge and cleavage of in vitro fertilized embryos. Fertil Steril 1988;49:479–82
   PubMedGoogle Scholar
• Martínez F, Coroleu B, Clua E, et al. Serum progesterone concentrations on the day of HCG administration cannot predict pregnancy in assisted reproduction cycles. Reprod Biomed Online 2004;8:183–90
   PubMed Web of Science ®Google Scholar